E. L. Parsadanova
Research Subjects
E. L. Parsadanova has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Alexey S. Kalpinskiy
P. A. Hertsen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia
3 shared publications - Yulia V. Anzhiganova
A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary
3 shared publications - Aleksei Shkurat
Leningrad Regional Clinical Hospital
2 shared publications - Andrey A. Lebedinets
Leningrad Regional Clinical Hospital
2 shared publications - I. S. Usoltseva
State Budgetary Healthcare Institution Sakhalin Regional Clinical Oncology Dispensary; Pacific State Medical University of the Ministry of Health of the Russian Federation
2 shared publications - Ilya Tsimafeyeu
Bureau for Cancer Research - BUCARE, New York, NY 10032, USA
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 4 (1) , 57-65
Clinical case of treatment of a patient with metastatic colorectal cancer with a POLE-mutation
Introduction. Metastatic colorectal cancer remains one of the major challenges in modern oncology due to its high incidence, frequent diagnosis at advanced stages, and the limited efficacy of standard lines of systemic therapy. In recent years, molecular genetic profiling of tumors has become increasingly important, enabling individualized selection of anticancer treatment. Mutations in the POLE gene are considered one of the potential biomarkers of sensitivity to immunotherapy. However, the clinical significance of individual POLE mutation variants remains ambiguous. Aim. To analyze a clinical case of treatment of a female patient with metastatic colorectal cancer and an identified POLE c.871G>A (p.Asp291Asn) mutation, with an assessment of the efficacy of PD-1 inhibitor immunotherapy. Materials and methods. This article presents a clinical observation of a female patient born in 1954 with stage IV sigmoid colon cancer and metastatic involvement of the liver, retroperitoneal lymph nodes, lungs, and mediastinal lymph nodes. The patient’s medical history, morphological and molecular genetic findings, sequence of systemic anticancer therapy, treatment tolerability, and clinical outcome were analyzed. Results. The patient sequentially received first-line systemic anticancer therapy with the XELOX regimen, followed by second-line therapy with cetuximab in combination with FOLFIRI and subsequent maintenance therapy with cetuximab plus de Gramont. Molecular genetic testing revealed no KRAS, NRAS, or BRAF mutations, no evidence of MSI, and no HER2 amplification; additionally, a POLE c.871G>A (p.Asp291Asn) mutation was detected. Due to disease progression, third-line immunotherapy with nivolumab was initiated. During treatment, disease stabilization was observed according to RECIST 1.1 criteria; however, a tendency toward growth of metastatic lesions persisted. Therapy was complicated by adverse events, including dermatologic toxicity, anemia, dyspeptic symptoms, and progression of chronic kidney disease to stage 4, which required discontinuation of the drug. Conclusion. The presented clinical case demonstrates that the presence of the POLE c.871G>A (p.Asp291Asn) mutation alone cannot be considered sufficient grounds for predicting the efficacy of immunotherapy in metastatic colorectal cancer. This variant is likely not among the functionally significant POLE mutations associated with ultrahigh tumor mutational burden and a pronounced response to immune checkpoint inhibitors. These findings highlight the need for comprehensive interpretation of POLE mutations, taking into account their functional significance, MSI status, TMB level, and clinical context before immunotherapy is prescribed.
- 12 October 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 4 (1) , 57-65
Open AccessClinical case of treatment of a patient with metastatic colorectal cancer with a POLE-mutation
Introduction. Metastatic colorectal cancer remains one of the major challenges in modern oncology due to its high incidence, frequent diagnosis at advanced stages, and the limited efficacy of standard lines of systemic therapy. In recent years, molecular genetic profiling of tumors has become increasingly important, enabling individualized selection of anticancer treatment. Mutations in the POLE gene are considered one of the potential biomarkers of sensitivity to immunotherapy. However, the clinical significance of individual POLE mutation variants remains ambiguous. Aim. To analyze a clinical case of treatment of a female patient with metastatic colorectal cancer and an identified POLE c.871G>A (p.Asp291Asn) mutation, with an assessment of the efficacy of PD-1 inhibitor immunotherapy. Materials and methods. This article presents a clinical observation of a female patient born in 1954 with stage IV sigmoid colon cancer and metastatic involvement of the liver, retroperitoneal lymph nodes, lungs, and mediastinal lymph nodes. The patient’s medical history, morphological and molecular genetic findings, sequence of systemic anticancer therapy, treatment tolerability, and clinical outcome were analyzed. Results. The patient sequentially received first-line systemic anticancer therapy with the XELOX regimen, followed by second-line therapy with cetuximab in combination with FOLFIRI and subsequent maintenance therapy with cetuximab plus de Gramont. Molecular genetic testing revealed no KRAS, NRAS, or BRAF mutations, no evidence of MSI, and no HER2 amplification; additionally, a POLE c.871G>A (p.Asp291Asn) mutation was detected. Due to disease progression, third-line immunotherapy with nivolumab was initiated. During treatment, disease stabilization was observed according to RECIST 1.1 criteria; however, a tendency toward growth of metastatic lesions persisted. Therapy was complicated by adverse events, including dermatologic toxicity, anemia, dyspeptic symptoms, and progression of chronic kidney disease to stage 4, which required discontinuation of the drug. Conclusion. The presented clinical case demonstrates that the presence of the POLE c.871G>A (p.Asp291Asn) mutation alone cannot be considered sufficient grounds for predicting the efficacy of immunotherapy in metastatic colorectal cancer. This variant is likely not among the functionally significant POLE mutations associated with ultrahigh tumor mutational burden and a pronounced response to immune checkpoint inhibitors. These findings highlight the need for comprehensive interpretation of POLE mutations, taking into account their functional significance, MSI status, TMB level, and clinical context before immunotherapy is prescribed.
- Open Access
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Open AccessAnalysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- Open Access
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Open AccessEfficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- Open Access
- 17 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 87-100
Multicenter non-interventional study of prevalence of homologous recombination gene mutations and approaches to treatment of metastatic castration-resistant prostate cancer in Russia (ADAM)
Background. Prostate cancer (PCa) is one of the most common cancers of men. In 2022, 48,025 new PCa cases and 12,896 deaths from the disease were reported in Russia. Metastatic castration-resistant PCa still is one of the common causes of death in men.Aim. To evaluate prevalence of homologous recombination repair gene (HRR) mutations in patients with metastatic castration-resistant PCa in Russia and to identify differences in clinical characteristics and treatment outcomes of patients with these mutations and without them.Materials and methods. The study included 329 patients with metastatic castration-resistant PCa from 20 centers. Patients underwent molecular genetic analysis using next-generation sequencing to identify mutations in 14 HRR genes. The mutation status was determined in 3 routine laboratories and further validated in a central independent laboratory.Results. The HRR gene mutations were detected in 59 (19.28 %) of 329 patients. The most common were ATM mutations – in 14 (4.57 %), BRCA2 – in 14 (4.57 %), BRCA1 – in 6 (1.96 %). All the patients received first-line therapy, with newgeneration antiandrogens and taxanes being used most frequently. The patients with HRR gene mutations had nearly1.5 times lower median of progression-free survival (PFS) with first-line therapy: 12.8 months vs. 20.8 months in patients without mutations (p = 0.048). There was statistically significant difference in PFS between the observed groups with first-line therapy depending on the treatment group. In patients of general group having been treated with new-generation antiandrogen therapy, the median of PFS was 22 months, while in patients who had received taxanes it was 8.22 months (p 0.05). In patients with HRR gene mutations having been treated with first-line antiandrogenes of novel generation, the median of PFS was 20.5 months, while in patients without mutations the PFS median was 23.1 months (p = 0.14). In patients with mutations and having been treated with first-line taxanes, the PFS median was 6.15 months, while in patients without mutations it was 8.55 months (p = 0.4).Conclusion. In our ADAM study in the Russian population, the proportion of carriers of the HRR gene mutations was slightly lower (19.28 %) than that reported in published randomized trials. There is also a different distribution structure and frequency of the most frequent mutations. Patients with the HRR gene mutations exhibited worse PFS rates and more aggressive course of the disease, which requires a special approach to treatment of this group of patients.
- 17 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 87-100
Open AccessMulticenter non-interventional study of prevalence of homologous recombination gene mutations and approaches to treatment of metastatic castration-resistant prostate cancer in Russia (ADAM)
Background. Prostate cancer (PCa) is one of the most common cancers of men. In 2022, 48,025 new PCa cases and 12,896 deaths from the disease were reported in Russia. Metastatic castration-resistant PCa still is one of the common causes of death in men.Aim. To evaluate prevalence of homologous recombination repair gene (HRR) mutations in patients with metastatic castration-resistant PCa in Russia and to identify differences in clinical characteristics and treatment outcomes of patients with these mutations and without them.Materials and methods. The study included 329 patients with metastatic castration-resistant PCa from 20 centers. Patients underwent molecular genetic analysis using next-generation sequencing to identify mutations in 14 HRR genes. The mutation status was determined in 3 routine laboratories and further validated in a central independent laboratory.Results. The HRR gene mutations were detected in 59 (19.28 %) of 329 patients. The most common were ATM mutations – in 14 (4.57 %), BRCA2 – in 14 (4.57 %), BRCA1 – in 6 (1.96 %). All the patients received first-line therapy, with newgeneration antiandrogens and taxanes being used most frequently. The patients with HRR gene mutations had nearly1.5 times lower median of progression-free survival (PFS) with first-line therapy: 12.8 months vs. 20.8 months in patients without mutations (p = 0.048). There was statistically significant difference in PFS between the observed groups with first-line therapy depending on the treatment group. In patients of general group having been treated with new-generation antiandrogen therapy, the median of PFS was 22 months, while in patients who had received taxanes it was 8.22 months (p 0.05). In patients with HRR gene mutations having been treated with first-line antiandrogenes of novel generation, the median of PFS was 20.5 months, while in patients without mutations the PFS median was 23.1 months (p = 0.14). In patients with mutations and having been treated with first-line taxanes, the PFS median was 6.15 months, while in patients without mutations it was 8.55 months (p = 0.4).Conclusion. In our ADAM study in the Russian population, the proportion of carriers of the HRR gene mutations was slightly lower (19.28 %) than that reported in published randomized trials. There is also a different distribution structure and frequency of the most frequent mutations. Patients with the HRR gene mutations exhibited worse PFS rates and more aggressive course of the disease, which requires a special approach to treatment of this group of patients.
- Open Access
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 122-128
When repeated biopsy dramatically changes treatment tactics in metastatic castration-refractory prostate cancer with neuroendocrine transformation: clinical case and literature review
Neuroendocrine neoplasia of the prostate gland is a rather rare neuroendocrine carcinoma characterized by poor prognosis. With an atypical course of prostate adenocarcinoma in certain cases, it is possible to suspect development of secondary neuroendocrine cancer. A timely repeat biopsy and correct diagnosis can affect both the patient’s life expectancy and his quality of life.
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 122-128
Open AccessWhen repeated biopsy dramatically changes treatment tactics in metastatic castration-refractory prostate cancer with neuroendocrine transformation: clinical case and literature review
Neuroendocrine neoplasia of the prostate gland is a rather rare neuroendocrine carcinoma characterized by poor prognosis. With an atypical course of prostate adenocarcinoma in certain cases, it is possible to suspect development of secondary neuroendocrine cancer. A timely repeat biopsy and correct diagnosis can affect both the patient’s life expectancy and his quality of life.